Faron

Faron is a clinical-stage biopharmaceutical company developing new treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on receptors involved in modulating immune responses in tumors and organ damage. Clevegen (bexmarilimab) is a novel anti-Clever-1 antibody with the ability to switch immunosuppression to immune activation, representing a new macrophage checkpoint immunotherapy under investigation as a precision immunotherapy in Phase I/II development. The company’s current pipeline focuses on acute organ trauma, vascular injury, and cancer immunotherapy.